Alcon Inc. · ALC · FY2025 Q3 · Calendar Q4 2025

Alcon: Unity and new products support maintained guidance

The current analysis supports a constructive but conditional view: product launches and procedure-related demand are improving the growth setup, while tariffs, competition and execution remain material constraints.

Why did ALC rise 2.7% after beating EPS estimates in FY2025 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported After market closeNYSEHealthcare $31.18B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $0.79 Consensus $0.77
EPS surprise +2.6% Reported versus consensus
Reported revenue $2.61B Consensus $2.71B
Revenue surprise -3.6% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

event-close to next-session close
Stock move +2.7% Event window
SPY move +0.1% Same window
Abnormal move +2.6% Stock minus SPY
Volume 2.5× Versus trailing sessions
Subsequent drift -0.9% Up to 20 sessions
ALCSPY benchmark

Ask FN2 about ALC FY2025 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior analysis, guidance sentiment moved from lowered to maintained. The current analysis emphasizes stronger Unity momentum, PanOptix Pro share stabilization and early Tryptyr adoption, while tariff and competitive risks persist.

Guidance delta

Guidance was maintained in the current analysis, reversing the prior quarter's lowered outlook; tariffs remain a margin headwind.

Key takeaways

  • Unity VCS equipment sales are accelerating and the current analysis cites efficiency gains for surgeons and facilities.
  • PanOptix Pro is stabilizing premium AT-IOL share, while Tryptyr is seeing early adoption.
  • Tariffs and competition remain the main offsets to the product-launch and demographic growth drivers.

Management priorities

  • Roll out Unity CS and expand Unity VCS workflow integration.
  • Broaden Tryptyr reimbursement, digital pharmacy fulfillment and direct-to-consumer support.
  • Expand PanOptix Pro and launch WaveLight Plus across additional markets.

Follow ALC with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ALC REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q3 '23 actual $2B, None Q4 '23 actual $2B, None Q1 '24 estimate $3B Q1 '24 actual $2B, miss Q2 '24 estimate $3B Q2 '24 actual $3B, miss Q2 '25 estimate $3B Q2 '25 actual $3B, miss Q3 '25 estimate $3B Q3 '25 actual $3B, miss Q4 '25 estimate $3B Q4 '25 actual $3B, miss Q1 '26 estimate $3B Q1 '26 actual $3B, beat Q2 '26 estimate $3B Q2 '26 actual $3B, beat Q3 '26 estimate $3B Q3 '26 actual $3B, beat Q4 '26 estimate $3B Q1 '27 estimate $3B Q2 '27 estimate $3B Q3 '27 estimate $3B
Show less

Analyst Consensus ?

ConsensusHold26 ratings
Bullish1453.8%
Neutral1038.5%
Bearish27.7%

Analyst 52W Price Targets

$74.31Current
$35Low
$87.16Average
$110High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Stifel Hold HoldMaintainNov 12, 2026
Barclays Equal Weight Equal WeightMaintainNov 12, 2026
Baird Outperform OutperformMaintainNov 12, 2026
Needham Buy BuyMaintainNov 11, 2026
BTIG Buy BuyMaintainNov 11, 2026
Show 21 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $74.31. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BernsteinSusannah Ludwig$88.9$72.8 +19.6%Nov 12, 2026
NeedhamDavid Saxon$98$71.45 +31.9%Nov 2, 2026
KeyBancAnalyst unavailable$84$69.99 +13.0%Oct 27, 2026
BTIGAnalyst unavailable$74$64.14 -0.4%Oct 12, 2026
BarclaysChristopher Pasquale$70$63.19 -5.8%Oct 6, 2026
See 46 more

Track every rating change on ALC the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as…

Historical context

All ALC earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain

Latest beats and misses

Who reports next

Get the ALC recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
  3. Polygon adjusted daily market bars · 2026-10-02T21:06:08.167885+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-02T21:06:08.164807+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-02. For educational purposes only; not investment advice.